老年糖尿病患者降糖药物减停的促进与阻碍因素:一项定性研究
该研究通过对15名65岁及以上、使用至少一种高风险降糖药或潜在不适当药物的糖尿病患者及10名家庭照护者进行半结构化访谈,识别影响减停降糖药意愿的因素。结果归纳为患者、处方者、药物和流程四类促进与阻碍因素,为制定针对性减停支持策略提供依据。
要点
- 患者层面促进因素包括理解处方者理由和偏好减少用药,阻碍因素为担心不良后果。
- 处方者信任、对诊疗投入的感知、专业能力及与其他处方者协作可促进减停。
- 逐步减量、详细随访计划及必要时可重启药物的选项是流程层面的促进因素。
核心结论
- 研究识别了影响患者和照护者减停降糖药意愿的关键促进与阻碍因素,可指导制定针对性支持策略。
研究设计与样本
- 对15名65岁及以上、使用至少一种高风险降糖药或潜在不适当药物的糖尿病患者及10名符合纳入标准的家庭照护者进行半结构化访谈,采用主题分析。
主要发现
- 促进与阻碍因素被归纳为患者相关、处方者相关、药物相关和流程相关四类。
- 患者相关促进因素包括理解处方者理由和偏好减少用药,阻碍因素包括担心不良后果。
- 处方者相关促进因素包括信任、感知的诊疗投入、感知的专业能力及与其他处方者协作。
- 药物相关阻碍因素包括感知的获益及缺乏影响生活质量的副作用。
- 流程相关促进因素包括逐步减量、详细随访计划及必要时可重启药物的选项。
临床怎么用
- 与老年糖尿病患者沟通减停降糖药时,应解释处方理由并评估其对不良后果的担忧。
- 建立信任、体现诊疗投入并与其他处方者协作,有助于提高减停接受度。
- 采用逐步减量、制定详细随访计划并保留必要时重启药物的选项,可促进减停实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over half of older adults with diabetes remain on overly intensive or inappropriate medication regimens to treat diabetes and related complications, leading to adverse drug events, polypharmacy, and increased risk of hospitalization and death. This study aimed to identify facilitators and barriers to deprescribing diabetes medications in this population. METHODS: We conducted 15 semi-structured interviews with adults aged 65 and older with diabetes who were on at least one high-risk hypoglycemic medication (e.g., sulfonylurea) or potentially inappropriate medication to treat diabetes-related peripheral neuropathy (e.g., tricyclic antidepressant) and 10 family caregivers of older adults meeting inclusion criteria. Interviews explored participants' general perspectives on diabetes medications, as well as barriers to and facilitators of following a prescriber's recommendation to deprescribe a diabetes medication. Interviews were audio recorded and transcribed verbatim. Two members of the research team developed a codebook, coded the transcripts, and reconciled any discrepancies. We then conducted a thematic analysis to identify key themes. RESULTS: We identified various factors influencing the views of patients and caregivers, which we categorized into four groups: patient-, prescriber-, medication-, and process-related facilitators and barriers. Patient-related facilitators included understanding of prescriber rationale and preference to minimize medications, while barriers included fear of negative consequences. Prescriber-related facilitators included trust, perceived investment in care, perceived expertise, and collaboration with other prescribers. Medication-related barriers included perceived benefit and a lack of side effects impacting quality of life. Lastly, process-related facilitators included a gradual reduction of medications, a detailed follow-up plan, and the option to restart the medication if necessary. CONCLUSION: We identified key facilitators and barriers that influence patients' and caregivers' willingness to have diabetes medications deprescribed. Our findings will inform the development of targeted strategies to support deprescribing diabetes medications in older adults.
引用
- Pickering AN, Richardson S, Rogal S, et al. Facilitators of and Barriers to Deprescribing Diabetes Medications in Older Adults: A Qualitative Study. J Am Geriatr Soc. 2025. PMID: 40471063. doi:10.1111/jgs.19550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。